Holen Sie sich die Stockscreener-App
8.22
1.91%
-0.16
Handel nachbörslich:
8.29
0.07
+0.85%
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
(BCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush - Insider Monkey
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by GW&K Investment Management LLC - MarketBeat
BCRXBioCryst Reports Full Year 2025 Financial Results and Provides Business Update - mx.advfn.com
Evercore ISI sees long-term growth potential for BioCryst Pharmaceuticals, Inc. (BCRX) following Astria acquisition - MSN
BioCryst Pharmaceuticals Conference: Profitability Pivot, ORLADEYO Growth, Navenibart Phase 3 Timeline - MarketBeat
BioCryst Pharmaceuticals Hits Day High with Strong 10.76% Intraday Surge - Markets Mojo
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Fisher Asset Management LLC - MarketBeat
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Its Profitability And Revenue Turnaround - simplywall.st
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
BioCryst (BCRX) Grants Stock Units to New Employees - GuruFocus
Director Jill C. Milne receives 528 BCRX shares as board retainer grant - Stock Titan
Biocryst (NASDAQ: BCRX) director executes option exercise and share disposition - Stock Titan
Director Vincent Milano gets 848 BIOCRYST (BCRX) shares as equity retainer - Stock Titan
BIOCRYST (BCRX) director Steven Frank receives 1,285-share stock retainer grant - Stock Titan
Director Amy McKee receives stock retainer award at BioCryst (BCRX) - Stock Titan
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Exploring a 146.81% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
BioCryst at TD Cowen Conference: Strategic Growth and Future Prospects - Investing.com
BioCryst Pharmaceuticals (BCRX) Is Up 15.4% After First Profitable Year And HAE Portfolio ExpansionHas The Bull Case Changed? - Sahm
BioCryst at TD Cowen Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com India
BCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BioCryst Pharmaceuticals, Inc. $BCRX Stock Holdings Boosted by Vanguard Group Inc. - MarketBeat
BioCryst Pharmaceuticals Receives $19.64 Consensus Price Target - National Today
[144] BIOCRYST PHARMACEUTICALS INC SEC Filing - Stock Titan
BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next - TechStock²
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Net Income Turns Positive And Astria Deal Expands HAE Portfolio - Yahoo Finance
BioCryst’s First Profitable Year Recasts Hereditary Angioedema Growth Story - Yahoo Finance
Price-Driven Insight from (BCRX) for Rule-Based Strategy - Stock Traders Daily
BioCryst (BCRX) Soars 10.8% on Swing to Profits - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE) - The Globe and Mail
BioCryst Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BCRX SEC FilingsBiocryst Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 10.7% After Earnings Beat - MarketBeat
Wedbush Adjusts Price Target on BioCryst Pharmaceuticals to $22 From $21, Maintains Outperform Rating - marketscreener.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2025 Earnings Call Transcript - Insider Monkey
10 Small-Cap Stocks With Huge Growth Potential - Insider Monkey
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
BioCryst Pharmaceuticals Inc (BCRX): A Strategic SWOT Insight - GuruFocus
Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Profitability Surge Tests Bullish Growth Narratives - simplywall.st
BioCryst: Q4 Earnings Snapshot - theheraldreview.com
BioCryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Highli - GuruFocus
BCRX: $400M Blackstone term loan funds Astria deal, secured by assets, matures 2031, SOFR+4.5% - TradingView
TD Cowen reiterates BioCryst Pharma stock Buy rating on Orladeyo growth By Investing.com - Investing.com South Africa
TD Cowen reiterates BioCryst Pharma stock Buy rating on Orladeyo growth - Investing.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Beats Expectations By $1.05 EPS - MarketBeat
BioCryst Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:BCRX) 2026-02-26 - Seeking Alpha
BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
BioCryst Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Earnings call transcript: BioCryst Q4 2025 sees EPS and revenue beat - Investing.com
BioCryst Pharmaceuticals' Q4 Swings to Earnings; Revenue Rises - marketscreener.com
BIOCRYST PHARMACEUTICALS ($BCRX) Releases Q4 2025 Earnings - Quiver Quantitative
Q4 2025 BioCryst Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q4 Total Revenue $406.6M - marketscreener.com
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q4 EPS $1.12 - marketscreener.com
BioCryst Boosts HAE Franchise With Astria Acquisition, Guidance - TipRanks
BioCryst: Fourth Quarter Financial Highlights - Bitget
BioCryst (BCRX) Achieves Record Revenue and Profitability Milest - GuruFocus
BioCryst Pharmaceuticals (BCRX) Projects Orladeyo Revenue to Rea - GuruFocus
BioCryst Pharmaceuticals : BCRX Q4 2025 Earnings Presentation - marketscreener.com
1.15%
3.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):